Oncology

Milestone Monday: What You'll Pay & Who You're Allowed to Pay It To

GSK spends $10.6bn to outrun a patent cliff while the Pentagon quietly reprices the supply chain underneath everyone. Two different bets on the same question: what is access actually worth.

Jun 15, 2026 Capsul Desk 10 min read members

A scientist in a white lab coat and blue gloves works at a lab bench, holding a pipette and looking down in concentration, with reagent bottles and supplies on the shelves beside him.

Therapeutic Thursday: The Crowd Is The Problem. Everyone Has A Different Solution.

Two of pharma's most crowded fields, and no agreement on whether the answer is to crowd in further or step away.

Jun 11, 2026 Aakash Babu 5 min read members

Milestone Monday: A $10.5 Billion China Bet And A Missing NDA

ASCO ended a week ago. The filing and the deal structure that deserve a closer look.

Jun 8, 2026 Capsul Desk 4 min read members

Therapeutic Thursday: The Deals Are Outrunning the Data in Oncology's Next Wave

Two qualify as first-in-class among 2032's ten biggest oncology bets. So why is big pharma paying nine figures for assets that haven't read out?

Jun 4, 2026 Capsul Desk 7 min read members

Trial Tuesday: China's ASCO Moment

For the first time in ASCO's history, China-only data occupies the plenary slot. A hazard ratio of 0.40 in pancreatic cancer. And Lilly moving the obesity ceiling above bariatric surgery. Chicago has a lot to answer for this week.

May 26, 2026 Manas Mishra 13 min read members

Page 1 of 1

Milestone Monday: What You'll Pay & Who You're Allowed to Pay It To

Therapeutic Thursday: The Crowd Is The Problem. Everyone Has A Different Solution.

Milestone Monday: A $10.5 Billion China Bet And A Missing NDA

Therapeutic Thursday: The Deals Are Outrunning the Data in Oncology's Next Wave

Trial Tuesday: China's ASCO Moment